HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for VYNE Therapeutics, maintaining a price target of $5.75.
September 12, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for VYNE Therapeutics, maintaining a price target of $5.75. This suggests confidence in VYNE's potential for growth.
The reiteration of a Buy rating and maintenance of a $5.75 price target by HC Wainwright & Co. indicates a positive outlook on VYNE's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100